sirna
trigger
rna
interfer
mechan
discov
late
releas
therapeut
potenti
versatil
larg
fragil
molecul
excipi
use
either
interact
electrostat
interact
passiv
encapsul
sirna
coval
attach
enabl
specif
safe
deliveri
drug
substanc
control
delic
balanc
protect
complex
releas
sirna
right
point
time
done
understand
excipientssirna
interact
lipid
polym
pei
plga
chitosan
cyclodextrin
well
aptam
peptid
review
describ
mechan
interact
commonli
use
sirna
deliveri
vehicl
look
result
clinic
preclin
studi
sinc
discoveri
late
rna
interfer
rnai
establish
invalu
tool
basic
research
also
rais
hope
medicin
find
novel
therapi
previous
undrug
target
diseas
find
rna
addit
classic
role
messeng
dna
encod
genet
inform
protein
product
also
function
regul
gene
express
led
quantum
leap
understand
gene
regul
rna
molecul
inhibit
protein
translat
either
bind
complementari
messeng
rna
mrna
therebi
block
ribosom
action
antisens
rna
microrna
trigger
degrad
mrna
molecul
catalyt
fashion
rnai
phenomenon
first
describ
caenorhabd
elegan
use
doublestrand
ds
rna
degrad
complementari
mrna
discoveri
led
nobel
prize
physiolog
medicin
fire
mello
state
art
gene
silenc
vitro
vivo
even
patient
via
singlestrand
antisens
oligodeoxynucleotid
odn
research
area
goe
back
year
two
class
molecul
similar
size
rang
charg
structur
lesson
learnt
formul
also
valid
sirna
formul
rna
interfer
howev
mediat
small
interf
doublestrand
rna
sirna
silenc
specif
target
gene
associ
multicompon
nucleas
call
rnainduc
silenc
complex
risc
guid
enzym
sequencespecif
degrad
complementari
mrna
mechan
demonstr
first
rang
mammalian
cell
vitro
show
sirna
effect
concentr
sever
order
magnitud
lower
antisens
ribozym
rna
advantag
antisens
technolog
mechan
discov
util
year
earlier
sirna
fda
approv
vitraven
antisens
base
ophthalm
drug
known
catalyt
cleavag
mrna
sirna
destroy
process
one
sirna
molecul
lead
cleavag
multipl
target
mrna
introduct
ds
rna
longer
basepair
bp
endogen
precursor
sirna
mammalian
cell
induc
strong
interferon
respons
sirna
hand
ds
rna
gener
bp
length
bind
target
high
degre
specif
therefor
potenti
use
transcrib
mrna
organ
genom
trigger
excit
drug
develop
field
research
tool
also
potenti
new
class
drug
molecul
versatil
compar
antibodi
sirna
also
endogen
express
follow
transfect
plasmid
viral
vector
viral
deliveri
sirna
also
demonstr
vivo
howev
concern
competit
nativ
microrna
pathway
well
interferon
respons
innat
immun
toward
longer
ds
rna
limit
applic
human
furthermor
potenti
immunogen
oncogen
well
high
cost
product
viral
vector
make
technolog
unlik
appli
clinic
use
therefor
cover
review
adenoassoci
viral
vector
aav
hand
shown
induc
less
immunogen
respons
current
evalu
gene
therapi
sever
clinic
trial
might
potenti
sirna
deliveri
vehicl
howev
toxic
issu
remain
resolv
move
drug
forward
plasmid
dna
antisens
rna
sirna
molecul
physicochem
properti
charg
densiti
common
also
fundament
differ
importantli
size
mechan
transfect
alway
compat
sirna
need
transport
cytosol
locat
rnai
machineri
wherea
plasmid
express
shrna
small
hairpin
rna
sirna
need
transport
nucleu
therefor
numer
nonvir
deliveri
method
investig
transfect
efficaci
well
toxic
properti
specif
molecular
natur
nucleic
acid
demand
special
formul
strategi
util
therapeut
potenti
rna
molecul
labil
acid
environ
stomach
endosom
lysosom
cell
destroy
enzymat
degrad
gastrointestin
tract
blood
circul
larg
size
kda
neg
charg
phosphodiest
backbon
neg
phosphat
charg
lead
electrostat
repuls
anion
cell
membran
surfac
limit
permeabl
cell
releas
endosom
articl
shed
light
promis
formul
effort
last
decad
led
first
rna
interfer
base
clinic
trial
summar
mechan
use
pursuit
turn
class
fragil
molecul
therapi
despit
properti
nake
sirna
shown
deliv
effici
vivo
although
mani
case
uptak
mechan
remain
unknown
first
success
vivo
demonstr
sirna
trigger
gene
silenc
report
nake
synthet
sirna
well
endogen
transcrib
hairpin
rna
deliv
liver
organ
mice
inhibit
codeliv
reportergen
sever
day
subsequ
treatment
hepat
potenti
therapeut
applic
describ
howev
experi
unmodifi
sirna
shrna
express
plasmid
deliv
quickli
inject
larg
volum
via
tail
vein
hydrodynam
tail
vein
inject
techniqu
restrict
rodent
applic
higher
anim
human
deliveri
unmodifi
sirna
via
portal
vein
potenti
clinic
relev
method
demonstr
equal
effici
hydrodynam
tail
vein
inject
vivo
protect
mice
viru
induc
liver
failur
lowpressur
intraven
iv
deliveri
nake
sirna
reach
wellperfus
organ
liver
kidney
report
also
show
chemic
stabil
sirna
introduc
phosphorothio
instead
phosphodiest
bond
see
fig
alter
biodistribut
increas
stabil
vitro
vivo
howev
subcellular
locat
describ
cell
uptak
remain
unproven
nake
chemic
unmodifi
sirna
short
halflif
blood
serum
even
though
stabl
singl
strand
rna
chemic
modif
sirna
residu
see
fig
end
cap
ribonucleotid
prolong
serum
minut
unmodifi
sirna
day
circul
min
min
addit
chemic
modif
also
reduc
signific
immun
stimul
otherwis
induc
unmodifi
sirna
similarli
backbon
modif
specif
posit
within
sirna
seed
region
abrog
unspecif
target
effect
cytokin
product
without
significantli
affect
silenc
intend
target
modif
toler
efficaci
specif
effect
chemic
modif
stabil
half
life
synergist
enhanc
upon
encapsul
commonli
use
chemic
modif
review
recent
nake
unmodifi
sirna
also
transport
cytoplasm
via
electropor
method
develop
plasmid
dna
regularli
use
transfect
sirna
vitro
also
describ
vivo
transfect
nake
sirna
deliv
use
slow
inject
muscl
tissu
mice
follow
ms
puls
v
hz
frequenc
set
prove
mild
safe
result
complet
repress
gene
express
day
tumor
necrosi
factor
tnf
sirna
inject
joint
follow
electropor
puls
vcm
reduc
collageninduc
arthriti
special
modifi
plate
fork
type
electrod
condit
deliveri
chemic
stabil
vegf
vascular
endotheli
growth
factor
sirna
optim
vcm
without
observ
gross
advers
event
loss
bodi
weight
correl
endogen
conduct
tumor
tissu
efficaci
deliveri
also
observ
conduct
correl
microvascular
densiti
therefor
vegf
concentr
tumor
method
vegf
express
microvascular
tumor
weight
could
significantli
reduc
xenograft
mous
tumor
model
electropor
tumor
system
sirna
administr
instead
directli
inject
tumor
higher
vegfsirna
concentr
requir
reach
effect
due
challeng
associ
nake
sirna
stabil
nake
sirna
applic
focus
local
administr
mucos
tissu
eye
six
year
discoveri
rnai
first
sirna
human
therapi
treatment
wet
age
relat
macular
degener
amd
sirna
therapeut
inc
enter
phi
clinic
trial
see
tabl
summari
ongo
clinic
trial
chemic
modifi
sirna
inject
intravitr
nake
entiti
concentr
mgey
without
sever
advers
event
although
low
amount
show
anticip
clinic
outcom
improv
foveal
thick
visual
acuiti
doserespons
effect
observ
thought
due
sequenceunspecif
reaction
tolllik
receptor
anoth
clinic
trial
start
also
use
free
sirna
silenc
vegf
treat
amd
intravitr
inject
mgey
studi
termin
earli
preliminari
data
indic
primari
endpoint
unlik
met
howev
dose
regimen
deliveri
vehicl
improv
outcom
consid
fact
nake
sirna
rapidli
clear
via
kidney
util
kidney
target
h
low
pressur
iv
administr
unmodifi
nake
radiolabel
sirna
rat
concentr
kidney
increas
compar
organ
select
downregul
target
also
observ
although
yet
identifi
sever
receptor
suggest
respons
uptak
oligonucleotid
kidney
effect
also
use
quark
pharmaceut
sirna
current
phi
clinic
trial
acut
renal
failur
kidney
transplant
local
deliveri
nake
unmodifi
sirna
target
gene
knockdown
also
success
vivo
lung
intranas
deliveri
deliveri
rout
result
certain
system
exposur
demonstr
sirna
administ
natur
calf
lung
surfact
infasurf
infasurf
pulmonari
surfact
compos
phospholipid
protein
abil
spread
line
alveoli
one
singl
intranas
administr
lead
approxim
knockdown
housekeep
protein
gapdh
lung
heart
kidney
day
alter
liver
protein
level
report
compar
intranas
codeliveri
unmodifi
sirna
plasmid
wv
dglucos
water
infasurf
solut
treat
scv
sar
coronaviru
induc
sar
sever
acut
respiratori
syndrom
mous
rhesu
macaqu
mice
deliveri
effici
infasurf
subsequ
nonhuman
primat
studi
scv
infect
sirnamedi
knockdown
conduct
demonstr
therapeut
efficaci
sirna
reliev
infect
induc
symptom
nake
sirna
administ
salin
shown
effect
treatment
respiratori
syncyti
viru
rsv
infect
demonstr
alnylam
antivir
phii
studi
although
nasal
administr
healthi
volunt
well
nebul
drug
lung
transplant
patient
prevent
rsv
infect
system
bioavail
report
minim
phiib
studi
current
recruit
patient
expect
conclud
indic
requir
system
exposur
formul
help
overcom
stabil
uptak
challeng
sirna
requir
deliveri
system
indic
depend
biolog
environ
target
applic
site
e
g
localsystem
excipi
protect
sirna
chemic
enzymat
degrad
exposur
releas
upon
arriv
target
site
system
administr
requir
rapid
renal
clearanc
avoid
ensur
particl
size
nm
hand
size
nanoparticl
exceed
nm
enabl
extravas
adequ
tissu
penetr
charg
high
enough
prohibit
selfaggreg
trigger
nonspecif
interact
cell
membran
plasma
protein
uptak
re
reticuloendotheli
system
mani
excipi
potenti
noncoval
complex
sirna
mostli
due
chargeinteract
advantag
use
deliveri
technolog
modular
tool
without
chemic
alter
drug
substanc
therebi
maintain
biodegrad
compon
eas
product
hand
interact
stabl
coval
bound
excipi
may
better
chanc
deliv
cargo
safe
target
tissu
howev
coval
modif
creat
new
chemic
entiti
thoroughli
toxicolog
character
time
formul
chang
light
formul
consid
part
drug
excipi
vast
varieti
excipi
class
provid
properti
variou
stage
preclin
clinic
explor
intrins
properti
phospholipid
abil
selfassembl
fluid
flexibl
vesicl
use
natur
traffic
biomolecul
within
well
cell
lipid
system
sirna
deliveri
mani
advantag
featur
cell
membran
consist
predominantli
phospholipid
eg
phosphatidylcholin
cholesterol
therefor
natur
lipid
biocompat
interact
cell
membran
deliv
payload
effici
cell
purifi
synthes
larg
quantiti
gener
two
lipid
deliveri
vehicl
consid
neutral
posit
charg
liposom
lipoplex
specif
differ
interact
drug
substanc
well
interact
cell
membran
liposom
compos
neutral
lipid
encapsul
sirna
aqueou
core
compar
low
entrap
effici
nucleic
acid
low
drug
lipid
ratio
compar
cation
liposom
hand
shown
toxic
vivo
eg
pulmonari
applic
toxic
effect
induc
reactiv
oxygen
intermedi
roi
correl
valenc
cation
lipid
speci
eleg
compromis
two
describ
encapsul
antisenseoligonucleotid
odn
use
ioniz
lipid
dodap
see
tabl
chemic
structur
common
lipid
approach
allow
effici
entrap
odn
formul
low
ph
thank
electrostat
interact
subsequ
adjust
ph
neutral
avoid
unfavor
biolog
effect
intraven
administ
nanoparticl
contain
posit
charg
amino
lipid
dodac
increas
amount
nucleic
acid
per
lipid
increas
lamellar
particl
indic
charg
interact
drive
forc
encapsul
cover
polyethylen
glycol
peg
increas
stabil
dodac
dodap
liposom
phosphorothio
odn
vivo
stabl
lipid
anchor
instead
peg
enhanc
effect
correl
ethanol
concentr
use
liposom
prepar
entrap
effici
describ
elsewher
high
ethanol
concentr
vv
ideal
achiev
high
entrap
effici
nucleic
acid
lipid
abl
flipflop
across
membran
region
enrich
nucleic
acid
deplet
pegceramid
suggest
focal
point
electrostat
interact
drug
substanc
excipi
subsequ
rearrang
multilamellar
structur
trap
nucleic
acid
lamella
increas
pegyl
stabil
liposom
result
increas
ethanol
requir
achiev
entrap
also
increas
final
entrap
effici
howev
larg
portion
peg
get
displac
formul
separ
free
pegceramid
micel
lipid
dodap
cation
formul
ph
becom
neutral
buffer
exchang
ph
releas
surfac
bound
unentrap
nucleic
acid
method
result
nucleic
acid
lipid
ratio
mass
order
magnitud
higher
passiv
encapsul
altern
low
encapsul
effici
sirna
neutral
liposom
lipophil
sirna
molecul
coval
conjug
lipid
molecul
coval
conjug
deriv
lauric
acid
lithochol
acid
cholesterol
unmodifi
sirna
enabl
sirna
deliveri
knockdown
vitro
cholesterol
modifi
chemic
stabil
sirna
shown
bind
human
serum
albumin
hsa
circul
estim
dissoci
constant
show
improv
vivo
pharmacokinet
properti
min
compar
min
unconjug
sirna
mice
unlik
unconjug
sirna
cholesterolconjug
detect
h
varieti
tissu
liver
heart
kidney
silenc
apob
mrna
liver
jejunum
result
decreas
plasma
level
apob
protein
cholesterol
transport
uptak
mechan
varieti
lipophil
chemic
stabil
sirna
conjug
cholesterol
fatti
acid
bile
acid
studi
vivo
sever
rodent
speci
conjug
interact
highdens
lipoprotein
hdl
follow
uptak
via
hdlreceptor
liver
gut
kidney
bind
low
densiti
lipoprotein
ldl
target
complex
mainli
ldlreceptor
liver
abil
bind
hdl
higher
longer
fatti
acid
chain
wherea
shortto
medium
fatti
acid
tend
bind
albumin
furthermor
preassembl
cholsirna
hdl
result
higher
silenc
efficaci
vivo
cholesterolsirna
alon
cation
lipid
transfect
describ
dna
alreadi
almost
year
ago
although
sirna
antisens
oligonucleotid
similar
physicochem
properti
plasmid
dna
lack
capac
condens
nanoparticl
upon
neutral
cation
lipid
one
pdna
molecul
collaps
form
nanoparticl
wherea
take
multipl
sirna
form
similar
structur
molecul
least
bp
requir
trigger
condens
effect
lead
reduct
size
result
favor
size
rang
long
vivo
circul
time
transfect
effici
minimum
persist
length
tabl
lipid
use
sirna
encapsul
deliveri
measur
polym
stiff
ds
nucleic
acid
nm
bp
consequ
bp
sirna
essenti
rigid
rod
dna
cocomplex
sirna
enhanc
deliveri
lipoplex
although
signific
structur
differ
particl
without
dna
observ
except
requir
lipid
per
nucleic
acid
form
complex
case
sirna
studi
cation
lipid
contain
globular
spermin
headgroup
use
combin
dope
also
transfect
reagent
micellar
lipofectamin
liposom
lesser
extend
polyethylenimin
pei
polym
nanoplex
show
increas
efficaci
coformul
plasmid
dna
effici
ratio
cation
lipid
nucleic
acid
efficaci
diminish
ratio
toxic
observ
presenc
serum
decreas
transfect
effici
lipoplex
zeta
potenti
complex
approach
zero
net
charg
surfac
neutral
repuls
electrostat
forc
otherwis
prevent
aggreg
absent
particl
size
increas
explan
higher
transfect
effici
may
poorer
entrap
subsequ
facilit
releas
sirna
presenc
pdna
polycation
liposom
transfect
reagent
dosper
roch
shown
trigger
rnai
vitro
cotransfect
plasmid
dna
synthet
oligonucleotid
duplex
similarli
iv
coinject
dotapcomplex
unmodifi
sirna
report
plasmid
dna
lead
effici
silenc
target
organ
liver
spleen
intraperiton
inject
sirna
complex
target
reduc
express
lipopolysaccharid
lp
challeng
without
increas
proinflammatori
cytokin
interleukin
il
suggest
therapeut
potenti
anoth
differ
sirna
pdna
antisens
rna
synthet
sirna
usual
enter
nucleu
transfect
rather
remain
perinuclear
region
show
conclus
drawn
transfect
experi
plasmid
antisens
dna
necessarili
transfer
sirna
transfect
also
term
sifect
recent
studi
suggest
use
cation
lipid
transfect
cell
unmodifi
sirna
lead
uptak
via
endocytosi
small
fraction
sirna
lipoplex
may
also
deliv
via
anoth
cholesteroldepend
rout
directli
cytoplasm
may
respons
major
mrna
degrad
result
may
indic
endosom
escap
major
bottleneck
function
sirna
deliveri
complex
nucleic
acid
lipid
employ
differ
state
depend
lipid
composit
shape
singl
lipid
molecul
rod
cone
shape
phase
transit
temperatur
invert
hexagon
liquidcrystallin
state
h
ii
nucleic
acid
surround
lipid
molecul
rodlik
fashion
stack
hexagon
lattic
multilamellar
structur
l
nucleic
acid
sandwich
flat
lipid
monolay
see
fig
structur
differ
dna
sirna
encapsul
cation
lipid
complex
thoroughli
investig
use
xray
diffract
show
minim
differ
although
h
ii
sirna
polyplex
show
higher
toxic
lower
vitro
efficaci
h
ii
dna
complex
higher
cation
lipidnucl
acid
molar
charg
ratio
requir
sirna
transfect
dna
furthermor
multival
cation
lipid
effici
sirna
transfect
reagent
monoval
lipid
nmr
analysi
nucleicacidlipid
nanoparticl
reveal
helperlipid
dope
cholesterol
promot
adopt
h
ii
phase
rather
lipid
bilay
enhanc
cation
lipidmedi
transfect
cell
abil
adopt
nonbilay
structur
correl
directli
unsatur
cation
lipid
decreas
bilayertoh
ii
transit
temperatur
bh
consequ
low
bh
indic
good
transfect
effici
ion
molecul
ca
polylysin
may
facilit
transit
therefor
enhanc
transfect
effici
cation
lipid
nanoplex
lipofectin
one
earliest
cation
lipid
transfect
reagent
nucleic
acid
transfer
compris
equimolar
mixtur
cation
lipid
dotma
colipid
dope
first
describ
use
antisens
rna
transfect
earli
dmriec
molar
ratio
liposom
formul
cation
lipid
dmrie
cholesterol
particl
nucleic
acid
associ
outsid
preform
liposom
nm
electrostat
interact
numer
proprietari
lipidbas
composit
transfect
agent
commerci
avail
mostli
design
vitro
cell
cultur
transit
tko
miru
base
lipid
polym
form
lipoplex
nucleic
acid
endocytos
effici
releas
cell
lipofectamin
launch
dna
transfect
optim
sirna
transfect
oligofectamin
lipofectamin
rnaimax
lipofectamin
transfect
unmodifi
sirna
prevent
experiment
coliti
rectal
administr
mice
similarli
oligofectamin
shown
enhanc
mucos
uptak
unmodifi
sirna
vivo
vagin
tissu
protect
mice
herp
simplex
viru
infect
reagent
show
toxic
experi
demonstr
feasibl
local
mucos
deliveri
sirna
oligofectamin
effici
reduc
mous
tumor
intraperiton
inject
unmodifi
sirna
howev
transfect
reagent
recommend
use
medium
without
serum
system
administr
describ
date
commerci
avail
transfect
system
describ
show
unspecif
total
cell
protein
knockdown
toxic
vitro
optim
specif
knockdown
low
toxic
achiev
use
cation
cholesterolbas
polyamin
lipid
cdan
neutral
helper
lipid
dope
transfect
unmodifi
sirna
studi
underlin
differ
formul
uptak
mechan
plasmid
dnaand
sirnalipoplex
well
formul
condit
salt
concentr
evid
cation
lipid
higher
affin
nucleic
acid
therefor
higher
load
capac
neutral
lipid
net
cation
charg
intraven
administ
lipidantisens
rna
nanoparticl
link
rapid
plasma
clearanc
due
opson
re
distribut
lung
liver
spleen
cation
lipid
alon
often
exhibit
liver
hemodynam
toxic
prolong
clot
time
shown
antisens
oligonucleotid
lipid
vesicl
unmodifi
sirna
transfect
cation
lipid
dotap
shown
trigger
unspecif
knockdown
offtarget
effect
vitro
due
activ
innat
immun
respons
sequenceand
concentrationdepend
manner
appear
depend
tlr
interact
signal
sinc
electropor
deliv
sirna
directli
cytoplasm
show
effect
effect
shown
singleand
doubl
strand
unmodifi
oligonucleotid
combin
lipid
trigger
immun
respons
immun
stimulatori
effect
trace
back
specif
gurich
sequenc
within
sirna
specif
format
molecul
substanti
dosedepend
activ
innat
immun
system
detect
upregul
inflammatori
cytokin
includ
demonstr
sever
mous
strain
also
requir
combin
vehicl
sirna
meanwhil
quest
optim
lipid
deliveri
vehicl
sirna
becom
systemat
larg
combinatori
librari
lipidlik
deliveri
molecul
term
lipidoid
gener
evalu
vitro
chemic
stabil
sirna
well
antisens
deliveri
sever
candid
shown
safe
efficaci
proceed
vivo
trial
rodent
nonhuman
primat
unlik
lipid
transfect
agent
best
perform
screen
contain
secondari
amin
two
aliphat
chain
shorter
typic
lipidoid
effect
lipofectamin
deliv
sirna
typic
hard
transfect
cell
macrophag
low
sirna
concentr
howev
display
vari
effici
differ
cell
line
order
provid
neutral
hydrophil
shell
reduc
opson
macrophag
uptak
vivo
particl
contain
also
cholesterol
pegconjug
efficaci
formul
shown
liver
target
iv
administr
well
pulmonari
periton
administr
liposom
also
allow
attach
target
ligand
antibodi
antibodi
use
gener
immunoliposom
target
dendrit
cell
deliv
unmodifi
sirna
vitro
vivo
dendrit
cell
rich
organ
silenc
target
mrna
report
posit
effect
incorpor
posit
charg
lipid
ddab
otherwis
neutral
liposom
base
popc
sirna
encapsul
effici
demonstr
anoth
report
nanoparticl
compos
cation
lipid
dotap
cholesterol
polycation
peptid
protamin
sulfat
modifi
anisamid
target
ligand
deliv
unmodifi
sirna
sigma
receptor
express
tumor
cell
time
effici
correspond
untarget
nanoparticl
vivo
administr
singl
iv
dose
sirnakg
result
gene
silenc
littl
report
immunotox
membran
destabil
effect
ethanol
encapsul
conjunct
stabil
effect
peglipid
use
gener
stabil
nucleic
acidlipid
nanoparticl
term
snalp
consist
lipid
bilay
contain
mixtur
cation
fusogen
lipid
enabl
cellular
uptak
endosom
releas
particl
payload
due
short
lipid
anchor
peg
molecul
shed
inject
circul
result
transfectioncompet
particl
therebi
chemic
stabil
sirna
circul
increas
min
h
encapsul
snalp
vivo
toxic
interferon
respons
sirna
decreas
without
compromis
activ
nonhuman
primat
snalp
base
lipid
dlindma
dspc
cholesterol
prove
effici
deliv
chemic
stabil
apobsirna
silenc
target
protein
lower
serum
cholesterol
lowdens
lipoprotein
level
detect
earli
h
administr
last
day
trigger
even
less
chang
clinic
relev
chemic
hematolog
paramet
blood
previous
publish
snalp
particl
prepar
nanoparticl
adapt
plasmidformul
method
ethanol
dilut
method
lipid
dissolv
ethanol
rapidli
mix
aqueou
sirna
solut
tshape
mix
chamber
instantan
dilut
ethanol
concentr
concentr
requir
support
lipid
solubl
result
particl
popul
narrow
size
distribut
antitumor
effect
snalpdeliv
chemic
stabil
sirna
confirm
hepat
also
subcutan
tumor
model
vivo
pololik
kinas
kinesin
spindl
protein
ksp
sirna
snalp
nanoparticl
also
prove
effici
polyethylenimin
pei
nanoparticl
protect
guinea
pig
ebola
viru
infect
use
unmodifi
sirna
tabl
give
overview
current
ongo
clinic
trial
use
snalp
technolog
new
potent
liposom
system
sirna
deliveri
term
atuplex
develop
atugen
ag
silenc
therapeut
base
cation
lipid
neutral
helper
lipid
dphype
mol
dspepeg
particl
modifi
sirna
sit
outsid
posit
charg
pegyl
liposom
instead
encapsul
snalp
particl
show
effici
sirna
deliveri
endosom
sirna
escap
knockdown
vitro
vivo
novel
lipid
highli
charg
head
group
allow
stronger
interact
sirna
compar
dotap
dotma
studi
also
effect
variou
degre
pegyl
studi
mol
abolish
vitro
transfect
effici
mol
pegyl
maintain
rnai
particl
could
detect
small
uniform
vesicl
insid
cell
vivo
mol
pegyl
prevent
unspecif
toxic
sideeffect
otherwis
observ
unpegyl
polyplex
demonstr
delic
balanc
transfect
effici
toxic
term
pegyl
sirna
nanoplex
base
composit
drug
sirna
develop
show
antitumorefficaci
rodent
nonhuman
primat
system
administr
downregul
sirna
target
protein
kinas
robust
lung
liver
tissu
due
high
vascular
due
sirna
sequenceunrel
unspecif
cytokin
activ
detect
formul
current
evalu
phi
clinic
trial
treatment
advanc
solid
tumor
preliminari
result
show
drug
well
toler
nine
patient
treat
achiev
stabl
diseas
repeat
treatment
two
experienc
slight
regress
tumor
metastas
class
polym
wide
use
nucleic
acid
deliveri
synthet
polym
polyethylenimin
organ
linear
branch
polym
molecular
weight
rang
kda
capac
pei
bind
nucleic
acid
form
selfassembl
nanoplex
similar
cation
lipid
due
posit
charg
howev
one
sixth
proton
amino
nitrogen
atom
proton
physiolog
ph
result
high
buffer
capac
releas
cargo
acid
environ
endosom
refer
proton
spong
effect
unproton
amin
polym
show
differ
acid
dissoci
constant
pka
valu
due
crowd
amin
display
buffer
effect
wide
rang
ph
buffer
may
protect
sirna
degrad
endosom
compart
matur
earli
endosom
late
endosom
subsequ
fusion
lysosom
buffer
capac
pei
caus
influx
proton
chlorid
ion
water
endosom
eventu
lead
swell
burst
endosom
due
increas
osmot
pressur
togeth
protect
effect
nucleas
circul
rel
low
vitro
toxic
led
pei
test
nucleic
acid
deliveri
agent
plasmid
oligonucleotid
alreadi
optim
drug
deliveri
system
sirna
reveal
lower
optim
ratio
nitrogen
phosphat
np
ratio
sirna
pdna
vs
use
linear
pei
led
vitro
target
downregul
compar
lipid
transfect
agent
oligofectamin
compar
pei
differ
degre
branch
molecular
size
np
ratio
show
transfect
effici
highli
depend
biophys
structur
characterist
particl
kda
branch
pei
bpei
np
ratio
show
specif
knockdown
without
unspecif
toxic
effect
vitro
low
efficaci
complex
n
p
ratio
trace
back
bigger
particl
size
overal
neg
zeta
potenti
complex
sirna
kda
pei
np
ratio
show
signific
silenc
efficaci
lung
iv
inject
mice
could
prevent
also
treat
alreadi
establish
influenza
infect
toxic
polyc
due
interact
neg
charg
cell
mitochondri
membran
lead
membran
damag
charg
depend
activ
complement
system
bpei
molecular
weight
mw
kda
higher
gener
believ
higher
effici
cytotox
compar
lower
mw
linear
pei
polyplex
pegyl
pei
gener
better
toler
pei
alon
one
detail
vitro
toxic
studi
compar
kda
pei
pegpei
polyethlylenglycolgraft
pei
use
varieti
vitro
assay
cell
viabil
ldh
releas
express
apoptosismark
confirm
better
toler
pegyl
pei
also
show
diblockcopolym
stimul
pathway
pei
variou
cell
line
demonstr
signific
assay
condit
compar
interpret
toxic
nanoplex
vegfsirna
coval
coupl
via
disulfid
linkag
peg
form
micel
electrostat
interact
branch
pei
core
protect
peg
corona
cleav
reduct
endosom
environ
result
sequencespecif
gene
silenc
vitro
intratrach
deliveri
unmodifi
sirna
via
unmodifi
fattyacid
modifi
peibas
nanocomplex
mice
lung
show
cytotox
despit
effici
knockdown
efficaci
pegyl
pei
reduc
cytotox
effect
hand
increas
immun
respons
inflamm
studi
demonstr
delic
balanc
hydrophil
peg
hydrophob
modif
respect
cytotox
immunostimul
effici
sirna
deliveri
water
solubl
lipopolym
wslp
base
kd
bpei
show
improv
deliveri
efficaci
antivegf
sirna
compar
convent
bpei
vitro
vivo
polym
neutral
condens
sirna
ww
ratio
wslpsirna
result
zeta
potenti
mv
reduc
cell
toxic
vitro
effici
protect
serum
degrad
intratumor
inject
peisirna
complex
mice
result
reduc
tumor
growth
compar
control
substitut
mol
primari
amin
branch
kda
pei
carboxyalkyl
chain
variou
length
result
significantli
reduc
cytotox
improv
silenc
efficaci
vitro
due
reduc
surfac
charg
increas
hydrophob
interact
unmodifi
pei
show
cytotox
effect
ww
ratio
effici
term
silenc
howev
modifi
pei
toler
effici
ratio
excess
modif
decreas
toxic
also
neutral
capac
therebi
efficaci
among
varieti
deriv
bpei
includ
ethyl
acryl
modifi
acetyl
neg
charg
propion
acid
substitut
amin
succinyl
appear
modif
result
lowest
toxic
sequenc
specif
knockdown
vitro
excess
modif
led
less
toxic
also
ineffect
polym
modif
pei
disulfid
bond
increas
degre
branch
enhanc
celluptak
intracellular
endosom
releas
silenc
effici
modifi
polym
complex
neutral
sirna
np
ratio
higher
hydrodynam
diamet
polyplex
correl
directli
np
ratio
reach
maximum
nm
np
ratio
higher
cellular
uptak
well
toxic
effect
increas
higher
polym
concentr
dose
depend
silenc
effect
howev
level
silenc
compar
cation
transfect
reagent
lipofectamin
rnaimax
ketal
version
pei
show
increas
cytoplasm
local
polyplex
follow
effici
releas
sirna
acidhydrolysi
amino
ketal
linkag
vitro
unmodifi
pei
target
sirna
partli
nucleu
addit
modifi
polym
also
lower
cytotox
serum
depend
unmodifi
pei
complex
effici
decreas
increas
mw
ketal
pei
evidenc
particl
size
ethidium
bromid
exclus
assay
transmiss
electron
microscopi
tem
possibl
result
steric
hindranc
interact
due
bulki
ketal
side
chain
howev
addit
primari
amin
ketal
branch
allow
closer
interact
sirna
therefor
better
retard
gel
lower
np
ratio
unmodifi
pei
branch
kda
pei
use
target
unmodifi
vegf
sirna
via
integrin
target
rgd
peptid
tumor
modifi
pei
condens
sirna
np
ratio
low
pegyl
decreas
surfac
charg
mv
suggest
local
rgdmodifi
peg
chain
surfac
particl
prevent
aggreg
otherwis
occur
unpegyl
pei
nanoplex
vitro
rgdtarget
unpegyl
sirnapei
nanoparticl
abl
enter
cell
inhibit
endogen
luciferas
express
pegyl
untarget
nanoparticl
show
effect
demonstr
decreas
interact
hydrophil
surfac
cell
particl
also
specif
decreas
tumor
angiogenesi
growth
inject
tumor
bear
mice
similar
activ
target
approach
folat
employ
target
peisirna
nanoparticl
folatereceptor
overexpress
cell
vitro
coval
pegyl
decreas
zeta
potenti
well
particl
size
due
charg
shield
effect
peg
kda
bpei
coval
attach
kda
peg
unstabil
sirna
via
disulf
linkag
combin
kda
bpei
np
ratio
lead
format
micel
nm
size
significantli
inhibit
vegf
express
tumor
growth
iv
well
intratumor
administr
tumor
mous
model
without
detect
inflammatori
respons
disulfid
linkag
effici
cleav
endogen
intracellular
concentr
mm
glutathion
releas
function
sirna
pei
encapsul
yeast
deriv
glucan
allow
target
sirna
macrophag
sever
organ
lung
liver
spleen
oral
administr
mice
macrophag
intestin
peyer
patch
transport
particl
across
intestin
lymphat
tissu
intraperiton
inject
unmodifi
sirna
complex
linear
low
molecular
weight
pei
jetpei
commerci
avail
polyplu
transfect
led
deliveri
intact
sirna
subcutan
tumor
reduct
tumor
growth
mous
xenograft
model
comparison
dnapei
particl
sirnapei
nanoplex
detect
exclus
cytoplasm
nucleu
anoth
studi
posit
charg
jetpeisirna
nanoparticl
effici
deliv
unmodifi
sirna
xenograft
tumor
result
knockdown
target
growth
factor
pleiotrophin
tumor
growth
regress
subcutan
intraperiton
administr
without
measur
stimul
immun
system
complex
also
inject
directli
central
nervou
system
glioblastoma
model
show
antitumor
effect
atom
forc
microscopi
afm
analysi
complex
reveal
peisirna
complex
spheric
shape
somewhat
smaller
size
compar
peidna
particl
lack
free
fiberlik
structur
stick
round
complex
indic
sirna
complet
cover
polym
polymer
nucleic
acid
deliveri
agent
shown
safe
clinic
trial
deliveri
pdna
via
intraves
infus
well
dermal
applic
howev
safe
system
administr
man
remain
proven
plga
water
insolubl
biodegrad
biocompat
polym
use
biopharmaceut
due
control
releas
characterist
howev
swell
particl
introduct
aqueou
medium
lead
releas
encapsul
drug
near
surfac
burst
releas
fashion
use
describ
first
sirna
encapsul
deliveri
effici
silenc
gfp
target
vitro
correl
process
paramet
load
effici
releas
sirna
plga
nanoparticl
investig
design
experi
plga
concentr
import
factor
increas
viscos
oil
phase
primari
emuls
result
decreas
leakag
sirna
outer
water
phase
result
encapsul
effici
high
burst
releas
surfaceloc
sirna
observ
follow
triphas
sustain
releas
month
plga
use
also
microspher
combin
kda
bpei
polyarginin
achiev
sustain
releas
unmodifi
antivegf
sirna
studi
month
vivo
evidenc
reduct
tumor
growth
intratumor
inject
mice
interact
termin
carboxyl
anion
plga
basic
amino
imino
group
arginin
pei
promot
high
encapsul
effici
reduc
burst
releas
topic
administr
unmodifi
sirna
mucos
tissu
plga
nanoparticl
demonstr
efficaci
nanoparticl
less
nm
encapsul
sirna
molecul
penetr
mucos
tissu
releas
sirna
sustain
fashion
day
singl
topic
administr
vagin
mucosa
led
reduct
target
express
less
inflammatori
respons
lipoplex
complex
sirna
spermidin
np
ratio
encapsul
plga
nanoparticl
increas
load
effici
particl
show
cytotox
effect
vitro
concentr
mgml
wherea
silenc
effici
compar
lipofectamin
rnaimax
summari
polym
may
first
choic
excipi
system
sirna
deliveri
agent
could
improv
formul
combin
excipi
due
sustain
releas
properti
cation
dendrim
extens
studi
poli
amidoamin
pamam
dendrim
polym
compos
multipl
coval
attach
branch
monom
eman
central
core
number
branch
point
precis
control
synthesi
defin
gener
g
higher
g
result
increas
surfac
group
closer
pack
higher
charg
densiti
dendrim
use
dna
deliveri
due
benefici
properti
defin
molecular
size
structur
homogen
high
densiti
function
group
first
efficaci
pamam
dendrimersirna
nanoparticl
describ
primari
amin
group
facilit
nucleic
acid
bind
neutral
sirna
np
ratio
low
trigger
proton
spong
endosom
burst
similar
polym
pei
nanos
particl
nm
protect
unmodifi
sirna
rnase
degrad
deliv
sirna
cell
vitro
interact
stabil
also
directli
correl
gener
dendrim
thermodynam
selfassembl
process
character
use
dynam
light
scatter
dl
smallangl
xray
scatter
sax
isotherm
titrat
calorimetri
itc
silico
model
recent
shown
increas
np
ratio
result
decreas
size
higher
polydispers
sirna
bind
alter
size
pamam
monom
nm
calorimetr
analysi
suggest
exotherm
biphas
bind
sirna
dendrim
bind
enthalpi
bind
kcalmol
molar
ratio
studi
investig
interact
polym
sirna
detail
silico
nmr
gel
retard
assay
reveal
increas
g
dendrim
becom
rigid
result
lower
bind
affin
furthermor
highli
ph
depend
effect
pronounc
gener
therefor
might
ideal
bind
well
endosom
releas
cargo
activ
pamamdendrim
commerci
qiagen
superfect
polyfect
use
mainli
plasmid
transfect
sirna
cocomplex
plasmid
dna
due
toxic
higher
gener
dendrim
vivo
studi
carri
pegyl
shown
decreas
toxic
dendrim
particl
also
improv
stabil
unmodifi
sirna
plasma
maintain
transfect
efficaci
polypropylenimin
dendrim
gener
complex
unmodifi
sirna
stabil
dithiol
crosslink
shield
peg
encapsul
method
substanti
decreas
otherwis
fast
releas
degrad
unmodifi
sirna
dendrimernanoplex
serum
due
pegyl
unspecif
interact
cell
surfac
decreas
target
peptid
trigger
specif
cell
uptak
gene
silenc
tumor
cell
line
mous
tumor
model
anoth
vivo
studi
nanoparticl
base
polymer
polyglycerol
dendrim
abl
stabil
unmodifi
sirna
induc
silenc
without
detect
toxic
effect
dendrimerbas
lysinecontain
nanoparticl
surfac
bound
lipid
chain
term
inop
stabil
apob
sirna
silenc
target
vitro
low
pressur
tail
vein
inject
particl
deliv
liver
spleen
lesser
extend
lung
silenc
apob
vivo
without
toxic
effect
maximum
silenc
effect
reach
dose
mgkg
result
knockdown
cyclodextrin
water
solubl
cyclic
oligosaccharid
use
pharmaceut
formul
due
solubil
properti
biocompat
low
toxic
immun
stimul
cyclodextrincontain
polym
cdp
base
sirna
nanoparticl
develop
biophys
character
vitro
cyclodextrin
premix
conjug
equimolar
ratio
ad
nucleic
acid
appropri
ratio
reach
desir
tunabl
charg
selfassembl
nanoparticl
adamantan
form
inclus
complex
high
associ
constant
pegmolecul
modifi
transferrin
enabl
activ
target
small
size
build
block
ensur
renal
clearanc
disassembl
although
enzymat
degrad
human
take
place
imidazol
group
attach
backbon
cyclodextrin
group
assist
endosom
releas
sirna
due
buffer
effect
particl
requir
slightli
posit
charg
ratio
complet
complex
protect
sirna
serum
enzym
pegyl
significantli
reduc
size
compar
unpegyl
particl
evidenc
light
scatter
afm
tem
use
isotherm
titrat
calorimetri
neg
observ
indic
releas
energi
upon
bind
hydrophob
adamantan
cyclodextrin
centrifug
filtrat
combin
multiangl
light
scatter
allow
calcul
stoichiometri
complex
particl
reveal
ratio
cdp
chain
sirna
molecul
adamantanepeg
molecul
transferrinpeg
molecul
uptak
cell
cultur
depend
transferrinconjug
confirm
confoc
microscopi
fac
analysi
vitro
result
use
differ
transferrindens
nanoparticl
surfac
evidenc
multival
transferrindecor
particl
increas
affin
transferrinreceptor
express
cell
due
avid
effect
led
releas
function
sirna
gene
silenc
deliveri
strategi
shown
slow
tumor
growth
mous
model
metastat
ewe
sarcoma
deliveri
mgkg
week
unmodifi
sirna
cyclodextrin
particl
via
low
volum
tailvein
inject
furthermor
increas
inflamm
marker
detect
observ
brain
metastas
affect
suggest
particl
cross
blood
brain
barrier
bbb
anoth
exampl
vivo
use
cyclodextrin
base
sirna
deliveri
vehicl
xenograft
tumor
mous
model
accumul
label
stabil
luciferas
sirna
tumor
show
signific
differ
whether
transferrin
attach
nanoparticl
luciferas
activ
reduct
tumor
significantli
higher
transferrintarget
sirna
nanoparticl
suggest
effici
endocytosi
activ
target
nanoparticl
doseescal
nonhuman
primat
studi
use
deliveri
vehicl
show
mild
revers
toxic
effect
kidney
liver
dose
mgkg
unmodifi
sirna
lower
dose
mgkg
well
toler
suggest
potenti
safe
use
formul
human
use
rel
rapid
clearanc
nanoparticl
plasma
ascrib
intend
tissu
target
base
multicompon
deliveri
vehicl
clinic
dosag
form
rondel
ultim
enter
first
formul
activ
target
sirna
phi
clinic
trial
contain
nonmodifi
sirna
target
ribonucleotid
reductas
subunit
promis
formul
produc
scalabl
cgmp
condit
dosag
form
complex
form
spontan
upon
mix
sirna
excipi
shown
nanoparticl
well
toler
cancer
patient
highest
dose
mgkg
accumul
tumor
melanoma
patient
investig
specif
cleavag
mrna
took
place
month
chitosan
posit
charg
biodegrad
linear
polysaccharid
compos
link
dglucosamin
nacetyldglucosamin
low
toxic
immunogen
pharmaceut
use
dietari
supplement
wound
heal
biomateri
mucoadhes
disrupt
properti
chitosan
suggest
applic
mucos
deliveri
potenti
chitosan
serv
excipi
nasal
deliveri
high
molecular
weight
compound
reflect
studi
insulin
deliveri
primari
amin
gener
alkalin
deacetyl
natur
sourc
chitin
becom
proton
ph
b
allow
bind
nucleic
acid
facilit
endosom
releas
protonspong
effect
describ
posit
charg
polym
zeta
potenti
nucleic
acidchitosan
nanoparticl
directli
link
deacetyl
degre
dd
thermodynam
interact
chitosan
nucleic
acid
describ
use
isotherm
titrat
calorimetri
enthalpi
format
nanoplex
order
magnitud
higher
liposom
peptidenucl
acid
interact
may
contribut
lower
biolog
activ
complex
due
high
stabil
prevent
nucleic
acid
releas
chitosan
sirna
deliveri
introduc
demonstr
selfassembl
nanoplex
nm
compos
kda
chitosan
dd
unmodifi
sirna
effici
protect
sirna
nucleas
degrad
silenc
egfp
vitro
sever
cell
line
similar
level
transittko
sirna
transfect
reagent
control
contrast
dna
sirna
report
requir
higher
mw
chitosan
effici
complex
knockdown
possibl
order
compens
shorter
size
sirna
studi
correl
size
dd
higher
knockdown
efficaci
vitro
shown
higher
mw
chitosan
higher
dd
optim
np
ratio
determin
use
kda
chitosan
dd
also
use
unmodifi
sirna
lower
higher
mw
chitosan
decreas
cell
viabil
contrast
studi
discuss
previous
lower
np
ratio
also
reduc
cell
viabil
cell
conflict
result
may
due
differ
cell
line
well
chitosan
batch
differ
supplier
may
react
differ
conclus
studi
compar
differ
deacetyl
chitosan
salt
form
sirna
deliveri
reveal
complex
capac
mainli
depend
weight
ratio
rather
salt
form
mw
chitosan
wherea
transfect
silenc
efficaci
vitro
influenc
weight
ratio
mw
optim
silenc
achiev
low
mw
chitosan
kda
weight
ratio
excess
sirna
demonstr
import
balanc
sirna
bind
releas
site
action
compar
pdna
complex
sirna
show
rather
weak
bind
slightli
posit
zeta
potenti
due
rigid
expos
structur
sirna
neutral
posit
charg
unlik
supercoil
pdna
alreadi
form
stabl
complex
weight
ratio
higher
sirna
complex
deacetyl
chitosan
kda
mass
excess
chitosan
result
reduct
gene
express
vitro
similar
lipofectamin
result
nanoparticl
nm
posit
zeta
potenti
mv
exhibit
irregular
lamellar
dendrit
structur
scan
electron
microscopi
sem
mainli
spheric
particl
use
afm
compar
simpl
ionic
complex
ionic
gelat
method
use
crosslink
tripolyphosph
produc
nanos
chitosan
sirna
particl
coval
crosslink
particl
show
better
vitro
silenc
efficaci
particl
size
correl
mw
chitosan
complet
complex
could
achiev
high
weight
ratio
chitosan
sirna
case
ttpcrosslink
ratio
ttp
chitosan
well
reaction
ph
affect
particl
size
low
n
p
ratio
result
transfect
compet
sirnananoparticl
use
differ
chitosan
fungal
origin
variou
dd
signific
proinflammatori
effect
vitro
itc
reveal
nanomolar
dissoci
constant
particl
chitosan
lower
molecular
weight
exhibit
regular
shape
particl
faster
cellular
uptak
higher
molecular
weight
chitosan
evidenc
tem
sax
confoc
microscopi
studi
point
differ
origin
fungu
vs
shrimp
purif
method
chitosan
may
signific
influenc
polyplex
format
could
one
reason
inconsist
result
throughout
literatur
concern
effici
n
p
ratio
toxic
due
instabl
complex
neutral
ph
vivo
studi
use
chitosan
sirna
deliveri
vehicl
report
howev
intraperiton
administr
sirnachitosan
nanoparticl
altern
deliveri
method
avoid
plasma
relat
protein
interact
reach
macrophagerich
environ
describ
knockdown
macrophag
result
reduct
target
gene
express
nanoparticl
prepar
use
chemic
stabil
sirna
kda
dd
chitosan
np
ratio
limit
use
chitosan
vivo
poor
solubl
ph
low
buffer
endosom
physiolog
ph
poor
cytoplasm
dissoci
kinet
imidazol
modif
primari
amin
kda
dd
chitosan
increas
transfect
efficaci
buffer
capac
solubl
report
pegyl
chitosangapdh
sirna
nanoparticl
np
ratio
result
signific
knockdown
target
gene
lung
liver
iv
administr
well
lung
intranas
administr
mice
without
advers
event
pegyl
nm
particl
decreas
charg
mv
mv
order
enhanc
vivo
transfect
efficaci
chitosan
complex
compos
polyisohexylcyanoacryl
pihca
unmodifi
sirna
coat
chitosan
complex
effici
deliv
sirna
subcutan
implant
breast
cancer
cell
iv
administr
show
toxic
effect
atelocollagen
highli
purifi
protein
deriv
calf
dermi
pepsin
digest
remov
potenti
antigen
telopeptid
attach
end
polym
due
low
toxic
low
immunogen
use
medicin
applic
wound
heal
cartilag
substitut
special
physic
properti
phase
chang
temperatur
liquid
gel
allow
local
target
posit
charg
lend
use
plasmid
dna
antisens
rna
deliveri
shown
stabil
sirna
coinject
tumor
vivo
xenograft
mous
tumor
model
facilit
transfect
unmodifi
sirna
appar
toxic
size
nucleic
acidatelocollagen
particl
could
control
nm
anoth
studi
look
self
assembl
nm
kda
atelocollagen
nanoparticl
sirna
protect
sirna
nucleas
degrad
revers
transfect
protocol
vitro
increas
cellular
uptak
silenc
efficaci
effici
liposom
transfect
vivo
particl
enabl
prolong
releas
unmodifi
sirna
silenc
efficaci
intratesticular
deliveri
orthotop
testi
tumor
model
system
deliveri
iv
inject
atelocollagensirna
nanoparticl
result
deliveri
sirna
gene
silenc
organ
liver
spleen
kidney
predominantli
tumor
xenograft
tumor
model
anoth
report
show
iv
inject
atelocollagencomplex
otherwis
nonmodifi
sirna
drug
deliv
tumor
includ
metastat
bone
tumor
without
induct
associ
toxic
atelocollagensirna
nanoparticl
deliv
mice
skelet
muscl
well
intraven
result
silenc
target
myostatin
increas
skelet
muscl
growth
demonstr
atelocollagen
nanoparticl
may
therapeut
use
util
enhanc
permeat
retent
epr
effect
target
tumor
also
diseas
tissu
hyaluron
acid
ha
neg
charg
nonsulf
glycosaminogluycan
polysaccharid
compos
altern
disaccharid
unit
nacetyldglucosamin
dglucuron
acid
natur
occur
extracellular
matrix
biocompat
biodegrad
led
use
tissu
engin
drug
deliveri
devic
ha
receptor
express
tumor
cell
util
port
entri
nanosc
formul
sinc
neg
charg
prohibit
electrostat
interact
nucleic
acid
particleform
forc
differ
strategi
employ
physic
entrap
coval
bind
sirna
disulfidecrosslink
ha
nanogel
prepar
invers
emuls
method
result
nm
particl
releas
sirna
upon
glutathion
treatment
simul
reduct
cytoplasmat
environ
nanoparticl
taken
hareceptor
overexpress
cell
without
induc
cytotox
show
similar
vitro
gene
silenc
efficaci
peisirna
complex
due
slightli
neg
charg
also
show
less
protein
bind
better
vitro
silenc
efficaci
presenc
serum
compar
pei
deliv
sirna
neg
charg
ha
also
use
conjunct
excipi
order
reduc
toxic
shield
charg
posit
charg
liposom
use
coval
hamodifi
dotapdop
lipid
ethanolinject
method
particl
smaller
nm
could
prepar
improv
bind
protect
properti
stabil
particl
compar
non
hamodifi
liposom
cytotox
reduc
hareceptor
depend
uptak
improv
vitro
conjug
branch
kda
pei
kda
ha
selfassembl
sirna
nm
nanoparticl
weight
ratio
sirna
peiha
taken
via
hareceptor
mediat
endocytosi
display
vitro
silenc
efficaci
lower
toxic
profil
pei
alon
complex
pegyl
chitosan
ha
prepar
ionotrop
gelat
techniqu
ha
crosslink
use
tripolyphosph
presenc
pegchitosan
follow
complex
sirna
result
particl
less
nm
protect
sirna
serum
degrad
deliv
sirna
cell
vitro
silenc
effici
compar
lipofectamin
low
toxic
studi
also
highlight
differ
complex
condens
pdna
compar
sirna
result
lower
sirna
encapsul
effici
nanoparticl
compar
pdna
also
sever
exampl
effici
safe
use
ha
combin
excipi
local
system
sirna
deliveri
vivo
plga
like
applic
ha
sirna
deliveri
vivo
combin
excipi
besid
cation
lipid
cation
polym
cell
penetr
peptid
cpp
third
class
posit
charg
molecul
evalu
nonvir
sirna
deliveri
vehicl
like
posit
charg
polym
charg
short
peptid
allow
spontan
interact
encapsul
sirna
also
facilit
interact
neg
charg
cell
membran
idea
use
peptid
carrier
drug
date
back
year
mpg
first
peptid
shown
form
noncoval
electrostat
stabil
complex
sirna
deliv
cargo
cell
recombin
amphipath
peptid
compos
hydrophob
fusion
sequenc
hiv
protein
hydrophil
domain
nuclear
local
sequenc
larg
antigen
mpg
initi
use
pdna
deliveri
therefor
contain
nuclear
local
signal
nl
mutat
adapt
nanocarri
cytoplasmat
deliveri
sirna
inhibit
studi
indic
uptak
follow
receptorindepend
pathway
propos
also
cpp
penetratin
insect
antennapedia
homeoprotein
transportan
neuropeptid
galanin
mastoparan
tatpeptid
deriv
transactiv
protein
cpp
deriv
sequenc
term
differ
mpg
peptid
describ
mutat
result
partial
helic
conform
studi
differ
uptak
mechan
silenc
efficaci
observ
whether
nl
mutat
neither
variant
deliv
sirna
nucleu
endosomelik
cytosol
vesicl
uptak
inhibit
low
temperatur
upon
addit
sever
endocytosi
inhibitor
suggest
driven
endocytot
process
amount
sirna
achiev
halfmaxim
inhibit
target
sirna
molecul
per
cell
case
peptid
deliveri
compar
molecul
lipofectamin
deliveri
suggest
lower
bioavail
peptidebound
sirna
might
due
less
effici
endosom
releas
peptid
deliv
sirna
mpg
peptid
optim
delet
amino
acid
improv
interact
sirna
well
lipid
cell
membran
contrast
previou
studi
result
particl
also
studi
term
size
charg
well
toxic
effect
cell
call
peptid
complex
unmodifi
sirna
molar
excess
peptid
result
particl
nm
zeta
potenti
mv
vitro
silenc
efficaci
higher
mpg
cell
toxic
observ
wherea
reduc
cell
viabil
intratumor
inject
selfassembl
cyclin
sirna
nanoparticl
complet
stop
tumor
growth
mgkg
dose
result
reduct
cyclin
mrna
level
order
improv
stabil
particl
circul
peptid
conjug
cholesterol
iv
inject
cholesterolmodifi
sirna
particl
result
surviv
mice
vs
cholesterolfre
sirna
formul
polyarginin
poa
base
amino
acid
sequenc
protein
transduct
domain
ptd
variou
viral
protein
use
deliveri
dsrna
plant
cell
optim
weight
ratio
sirna
poa
found
complet
complex
sirna
poa
also
use
conjug
peg
combin
cation
lipid
encapsul
sirna
molar
excess
result
particl
nm
charg
mv
downregul
gfp
protein
express
vitro
higher
unpegyl
pegyl
liposom
without
poa
cell
viabil
incub
nm
sirna
complex
also
increas
upon
addit
poa
compar
formul
peg
alon
anoth
approach
modif
polyarginin
myrist
acid
moieti
mpap
increas
affin
lipid
bilay
membran
therebi
enhanc
peptid
entri
mpap
also
abil
cross
blood
brain
barrier
util
neurolog
applic
molar
ratio
sirna
mpap
abl
complex
sirna
protect
partial
serum
degrad
deliv
neuron
cell
result
target
knockdown
vitro
without
cytotox
hydrophob
modif
ntermin
conjug
cholesterol
oligodarginin
peptid
util
synergist
increas
cellular
uptak
sirna
complet
complex
sirna
reach
np
ratio
compar
pdna
cell
viabil
remain
incub
complex
np
ratio
cell
higher
ratio
drastic
increas
toxic
multifunct
envelopetyp
nanodevic
mend
compos
stearyl
octaarginin
cover
dopechem
molar
ratio
lipid
membran
condens
sirna
nanosc
particl
nm
transfect
cell
vitro
via
macropinocytosi
np
ratio
complex
particl
contain
nm
sirna
show
signific
effect
hela
cell
viabil
polyllysin
pll
protamin
also
test
fail
condens
sirna
particl
smaller
nm
condens
nanoparticl
alon
could
transfect
cell
depend
lipid
envelop
contrast
anoth
report
achiev
rnai
effect
use
liposom
bear
molecul
attach
liposom
surfac
deliv
unmodifi
sirna
vitro
lung
tumor
cell
particl
selfassembl
mix
egg
pc
dotap
cholesterol
sirna
ratio
result
neutral
posit
neg
charg
subsequ
addit
result
particl
rang
nm
compos
smaller
spheric
particl
nm
revers
order
mix
ad
sirna
preform
particl
result
weaker
bind
support
hypothesi
upon
heat
preform
lipidsirna
nanoparticl
lipid
molecul
rearrang
small
invert
hexagon
micel
incorpor
one
singl
sirna
molecul
subsequ
arrang
form
bigger
particl
cover
second
layer
lipid
particl
effici
protect
sirna
serum
degrad
deliv
sirna
variou
cell
line
vitro
fashion
less
toxic
lipofectamin
concentr
lipid
affect
cell
viabil
ha
use
shield
toxic
effect
polylarginin
complex
unmodifi
sirna
posit
charg
nm
taken
led
sequencespecif
silenc
independ
presenc
serum
intratumor
inject
hananoparticl
also
result
target
silenc
mice
howev
possibl
toxic
effect
investig
vivo
cpp
penetratin
transportan
link
via
ctermin
cystein
residu
thiol
contain
sens
strand
sirna
shown
sirna
sens
strand
abrog
silenc
efficaci
wherea
maintain
silenc
efficaci
howev
high
dose
use
reach
knockdown
compar
lipofect
anoth
technic
complic
appear
anneal
two
sirna
strand
modif
sens
strand
highli
cation
lipid
contrast
coval
conjug
sirna
penetratin
transportan
via
acid
labil
disulfid
bond
result
better
deliveri
characterist
cation
liposom
peptid
deliv
sirna
without
endocytosi
directli
cytoplasm
disulfid
bond
cleav
anoth
cpp
use
sirna
deliveri
deriv
protamin
small
arginin
rich
protein
endogen
involv
dna
packag
use
antibodyprotamin
fusion
protein
eleg
solut
noncoval
complex
sirna
target
diseas
cell
tissu
fab
fragment
target
envelop
antigen
deliv
unmodifi
sirna
specif
cell
express
antigen
vitro
vivo
without
trigger
interferon
respons
obviou
toxic
effect
meanwhil
strategi
employ
sever
target
human
integrin
lymphocyt
functionassoci
vitro
vivo
scid
mous
xenograft
tumor
model
particl
specif
deliv
unmodifi
sirna
target
express
cell
system
administr
similar
approach
mgkg
protaminecondens
sirna
entrap
liposom
decor
fabmodifi
ha
revers
coliti
system
administr
mice
condens
unmodifi
sirna
protamin
allow
high
drug
load
per
nanoparticl
sirna
molecul
protect
liposom
interferon
product
respons
sirna
activ
target
uptak
mechan
coupl
fabfrag
electrostat
interact
also
dsrna
bind
domain
employ
bind
sirna
result
effici
transfect
vitro
lipofectamin
sever
cell
line
includ
cell
primari
cell
tatptd
protein
transduct
domain
fusion
protein
induc
signific
toxic
effect
investig
cell
line
reduc
target
gene
express
luciferas
mous
model
nasal
administr
pmol
complex
luc
sirna
despit
promis
report
vivo
applic
studi
investig
toxic
vitro
predict
potenti
immun
respons
repeat
dose
cpp
appropri
vivo
model
need
consid
sinc
immunodefici
mice
often
use
xenograft
model
induct
unspecif
toxic
immun
stimul
peptid
may
limit
vivo
use
evidenc
tat
penetratin
sirna
deliveri
mous
lung
although
conjug
sirna
coval
attach
tat
penetratin
peptid
via
disulfid
enabl
sirna
deliveri
sirnaspecif
knockdown
cell
cultur
intratrach
administr
tatpeptid
reduc
target
mrna
express
suggest
toxic
effect
peptid
penetratinsirna
conjug
activ
innat
immun
respons
indic
differ
uptak
mechan
tatmedi
deliveri
endosom
releas
sirna
anoth
difficulti
sirna
deliveri
cytosol
new
synthet
cell
penetr
peptid
call
promis
potenti
effici
sirna
transfect
sever
cell
line
vitro
well
varieti
organ
mous
vivo
potent
proton
acceptor
trifluoromethylquinolin
attach
peptid
mix
unmodifi
sirna
spontan
form
nanoparticl
approx
nm
mv
act
proton
spong
endosom
facilit
endosom
releas
stearic
acid
moieti
coval
attach
cpp
increas
serum
stabil
unlik
cpp
base
nanoparticl
particl
remain
stabl
sever
week
knockdown
achiev
kidney
lung
liver
appar
toxic
immunogen
sideeffect
aptam
synthet
nucleic
acid
select
random
sequenc
librari
optim
abil
bind
specif
target
molecul
nanoto
picomolar
dissoci
constant
synthesi
sirna
aptam
chimera
allow
activ
target
use
rna
instead
antibodi
principl
versatil
antibodi
low
immunogen
synthes
larg
quantiti
rel
low
cost
modifi
increas
resist
degrad
improv
pharmacokinet
vivo
smaller
size
compar
antibodi
vs
kda
improv
tissu
penetr
shown
target
sirna
cell
surfac
receptor
psma
overexpress
prostat
cancer
cell
reduc
tumor
size
upon
intratumor
inject
therapeut
sirnachimera
fact
construct
actual
dicer
substrat
may
reason
effici
incorpor
result
sirna
risc
complex
fusion
construct
optim
increas
effici
eas
product
pharmacokinet
properti
vivo
use
result
molecul
capabl
reduc
tumor
growth
mice
even
system
administr
instanc
coupl
kda
peg
group
increas
circul
min
h
decreas
requir
dose
reach
therapeut
effect
vivo
target
psma
use
anoth
report
deliv
sirna
cancer
cell
use
biotinstreptavidin
linker
without
cleavabl
disulfid
linker
dicersubstr
sirna
use
aptam
induc
sequenc
specif
knockdown
compar
oligofectamin
facilit
silenc
without
interferon
respons
although
tetram
streptavidin
provid
bind
site
therefor
would
enabl
bind
four
differ
sirna
immunogen
biotinstreptavidin
compon
still
pose
hurdl
pharmaceut
util
coupl
chemistri
anoth
studi
target
glycoprotein
allow
silenc
tatrev
inhibit
hiv
replic
vitro
dicersubstr
sirna
link
aptam
alreadi
potenc
decreas
hivinfect
therefor
serv
target
devic
therapeut
agent
chimera
synthes
vitro
bacteriophag
transcript
anneal
antisens
strand
rna
induc
ifn
respons
cell
cultur
sirna
compris
class
therapeut
molecul
discov
one
decad
ago
sinc
trigger
lot
excit
pharmaceut
area
due
intrins
versatil
specif
initi
enthusiasm
led
mani
pharmacompani
start
sirna
program
develop
sirna
base
therapi
turn
challeng
expect
lead
termin
program
restructur
roch
specif
physicochem
properti
mani
case
demand
formul
protect
molecul
biolog
environ
facilit
deliveri
target
site
review
discuss
common
deliveri
sirna
strategi
whether
specif
encapsul
strategi
appli
particular
therapi
depend
whether
indic
anticip
administr
dose
regimen
allow
use
certain
substanc
ethanol
cholesterol
fatti
acid
list
current
ongo
clinic
trial
suggest
high
unmet
medic
need
cure
diseas
cancer
convinc
increasingli
conserv
health
author
easili
approv
novel
excipi
might
approv
indic
although
number
excipi
investig
potenti
overcom
challeng
sirna
deliveri
hurdl
vivo
proceed
human
trial
nake
sirna
formul
obvious
simplest
cheapest
format
howev
limit
local
administr
lung
eye
also
kidney
system
administr
lipid
formul
system
system
drug
deliveri
hand
head
start
excipi
liposom
research
go
mani
decad
vivo
fate
well
understood
lead
formul
snalp
atuplex
except
exampl
cyclodextrin
base
rondel
formul
show
novel
complex
formul
legitim
option
provid
certain
unmet
medic
demand
address
mani
novel
excipi
would
still
undergo
expens
timeconsum
toxicolog
studi
proceed
clinic
numer
vitro
vivo
studi
tri
shed
light
toxicolog
profil
innov
deliveri
system
howev
absenc
systemat
comparison
due
differ
protocol
cell
line
assay
vivo
model
result
often
inconsist
controversi
furthermor
upscal
gmp
requir
excipi
well
manufactur
protocol
rare
taken
consider
novel
deliveri
technolog
investig
consequ
futur
rnai
therapi
depend
willing
pharma
compani
invest
long
term
healthcar
system
pay
result
price
therapi
howev
sinc
field
rnai
still
rel
young
number
ongo
clinic
trial
also
success
preclin
vivo
studi
nevertheless
promis
therapeut
well
commerci
potenti
molecul
